The upcoming May regulatory calendar appears relatively light, with only five key FDA decisions expected. Despite the limited number of events, the slate includes several potentially meaningful label expansions across major therapeutic areas.
Let's take a closer look at what's ahead for the month.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com